Higher antibody responses after mRNA-based vaccine compared to inactivated vaccine against SARS-CoV-2 in Behcet's syndrome

Basit Öğe Kaydı
dc.authoridSeyahi, Emire/0000-0003-4965-2918
dc.authoridYilmaz, Erkan/0000-0002-5133-4532
dc.authoridOzdede, Ayse/0000-0002-6531-8138
dc.authoridHamuryudan, Vedat/0000-0001-6625-1652
dc.authoridTuyji Tok, YESIM/0000-0003-4970-9216
dc.authoridNohut, Okan Kadir/0000-0002-8111-8072
dc.contributor.authorOzdede, Ayse
dc.contributor.authorNohut, Okan Kadir
dc.contributor.authorAtli, Zeynep
dc.contributor.authorTok, Yesim Tuyji
dc.contributor.authorGuner, Sabriye
dc.contributor.authorYilmaz, Erkan
dc.contributor.authorUcar, Didar
dc.date.accessioned2025-03-23T19:44:37Z
dc.date.available2025-03-23T19:44:37Z
dc.date.issued2022
dc.departmentSinop Üniversitesi
dc.description.abstractThere are limited data about humoral response to vaccine in Behcet's syndrome (BS). We compared SARS-CoV-2 antibody response after two doses of inactivated (Sinovac/CoronaVac) or mRNA (Pfizer/BioNTech) vaccines in patients with BS and healthy controls (HCs). We studied 166 (92M/74F) patients with BS (mean age: 42.9 +/- 9.6 years) and 165 (75M/90F) healthy controls (mean age: 42.4 +/- 10.4 years), in a single-center cross-sectional design between April 2021 and October 2021. A total of 80 patients with BS and 89 HCs received two doses of CoronaVac, while 86 patients with BS and 76 HCs were vaccinated with BioNTech. All study subjects had a negative history for COVID-19. Serum samples were collected at least 21 days after the second dose of the vaccine. Anti-spike IgG antibody titers were measured quantitatively using a commercially available immunoassay method. We found that the great majority in both patient and HC groups had detectable antibodies after either CoronaVac (96.3% vs 100%) or BioNTech (98.8% vs 100%). Among those vaccinated with CoronaVac, BS patients had significantly lower median (IQR) titers compared to HCs [36.5 (12.5-128.5) vs 102 (59-180), p < 0.001]. On the other hand, antibody titers did not differ among patients with BS and HCs who were vaccinated with BioNTech [1648.5 (527.0-3693.8) vs 1516.0 (836.3-2599.5), p = 0.512). Among different treatment regimen subgroups in both vaccine groups, those who were using anti-TNF-based treatment had the lowest antibody titers. However, the difference was statistically significant only among those vaccinated with CoronaVac. Among patients vaccinated with BioNTech, there was no statistically significant difference between different treatment regimen groups. Compared to inactivated COVID-19 vaccine, mRNA-based vaccine elicited higher antibody titers among BS patients. Only in the CoronaVac group, patients especially those using anti-TNF agents were found to have low titers compared to healthy subjects. BS patients vaccinated with BioNTech were found to have similar seroconversion rates and antibody levels compared to healthy controls. Further studies should assess whether the low antibody titers are associated with diminished protection against COVID-19 in both vaccine groups.
dc.description.sponsorshipTurkish Rheumatology Society [13]
dc.description.sponsorshipThe authors have received financial support from Turkish Rheumatology Society, 11.12.2022, no: 13.
dc.identifier.doi10.1007/s00296-022-05164-7
dc.identifier.endpage1750
dc.identifier.issn0172-8172
dc.identifier.issn1437-160X
dc.identifier.issue10
dc.identifier.pmid35779083
dc.identifier.scopus2-s2.0-85133304925
dc.identifier.scopusqualityQ1
dc.identifier.startpage1741
dc.identifier.urihttps://doi.org/10.1007/s00296-022-05164-7
dc.identifier.urihttps://hdl.handle.net/11486/6982
dc.identifier.volume42
dc.identifier.wosWOS:000819911300001
dc.identifier.wosqualityQ2
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherSpringer Heidelberg
dc.relation.ispartofRheumatology International
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/openAccess
dc.snmzKA_WOS_20250323
dc.subjectImmunity
dc.subjectHumoral
dc.subjectCOVID-19
dc.subjectVaccine
dc.subjectBehcet's syndrome
dc.subjectBioNTech
dc.subjectCoronaVac
dc.titleHigher antibody responses after mRNA-based vaccine compared to inactivated vaccine against SARS-CoV-2 in Behcet's syndrome
dc.typeArticle

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu